GUD Insider Trading (Knight Therapeutics)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$1,095,637.90
Insider Selling (Last 12 Months): C$0.00
Knight Therapeutics Share Price & Price History
Current Price: C$5.31
Price Change: ▲ Price Increase of +0.1 (1.92%)
As of 05/20/2022 01:00 AM ET
How You Should Be Choosing Your Stocks
From Vantage Point | Ad
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.
Knight Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/18/2022 | Long Zone Holdings Inc. | Insider | Buy | 20,000 | C$5.17 | C$103,400.00 | 21,705,933 | |
| 5/18/2022 | Samira Sakhia | Director | Buy | 19,305 | C$5.18 | C$99,999.90 | 136,734 | |
| 4/13/2022 | Janice Jean Murray | Director | Buy | 1,900 | C$5.30 | C$10,070.00 | 6,115 | |
| 12/23/2021 | Jonathan Ross Goodman | Director | Buy | 3,600 | C$5.24 | C$18,864.00 | 765,059 | |
| 12/13/2021 | Samira Sakhia | Director | Buy | 15,800 | C$5.20 | C$82,160.00 | 83,786 | |
| 12/3/2021 | Jonathan Ross Goodman | Director | Buy | 19,200 | C$5.21 | C$100,032.00 | | |
| 11/22/2021 | Jonathan Ross Goodman | Director | Buy | 800 | C$5.23 | C$4,184.00 | 672,984 | |
| 11/22/2021 | Long Zone Holdings Inc. | Insider | Buy | 18,000 | C$5.29 | C$95,220.00 | 21,685,133 | |
| 11/19/2021 | Robert Nathaniel Lande | Director | Buy | 15,000 | C$5.39 | C$80,850.00 | 260,614 | |
| 11/19/2021 | Robert Nathaniel Lande | Director | Buy | 15,000 | C$5.39 | C$80,850.00 | 260,614 | |
| 11/15/2021 | Jonathan Ross Goodman | Director | Buy | 18,000 | C$5.25 | C$94,500.00 | 654,184 | |
| 9/20/2021 | Arvind Utchanah | Senior Officer | Buy | 600 | C$5.20 | C$3,120.00 | 9,913 | |
| 8/23/2021 | Jonathan Ross Goodman | Director | Buy | 4,300 | C$5.36 | C$23,048.00 | 631,788 | |
| 8/18/2021 | Jonathan Ross Goodman | Director | Buy | 18,000 | C$5.39 | C$97,020.00 | 609,488 | |
| 7/14/2021 | Jonathan Ross Goodman | Director | Buy | 18,000 | C$5.30 | C$95,400.00 | 591,488 | |
| 7/2/2021 | Jonathan Ross Goodman | Director | Buy | 18,000 | C$5.24 | C$94,320.00 | 555,488 | |
| 5/25/2021 | Jonathan Ross Goodman | Director | Buy | 2,400 | C$5.25 | C$12,600.00 | 502,361 | |
| 1/13/2021 | Robert Nathaniel Lande | Director | Buy | 17,000 | C$5.27 | C$89,590.00 | 72,714 | |
| 1/6/2021 | Long Zone Holdings Inc. | Insider | Buy | 200 | C$5.29 | C$1,058.00 | 21,656,133 | |
| 9/15/2020 | Robert Nathaniel Lande | Director | Buy | 414 | C$6.04 | C$2,500.56 | 46,128 | |
| 7/11/2019 | Robert Nathaniel Lande | Director | Buy | 20,000 | C$7.52 | C$150,300.00 | 45,392 | |
| 6/21/2019 | Long Zone Holdings Inc. | Insider | Buy | 12,000 | C$7.59 | C$91,080.00 | 21,633,433 | |
Warning: The Last Value Play Gone After August?
From Oxford Club | Ad
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.
But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
SEC Filings (Institutional Ownership Changes) for Knight Therapeutics (TSE:GUD)
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
Read More on Knight Therapeutics
Today's Range
Now: C$5.31
52 Week Range
Now: C$5.31
Volume
119,043 shs
Average Volume
231,313 shs
Market Capitalization
C$612.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Knight Therapeutics?
